article thumbnail

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Pharma Mirror

The post The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy appeared first on Pharma Mirror Magazine. 2] Presumably, fenbendazole multitherapy along with this little. 2] Presumably, fenbendazole multitherapy along with this little.

article thumbnail

DuPont Announces Research Collaboration with Rutgers University

Pharma Mirror

The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation. The post DuPont Announces Research Collaboration with Rutgers University appeared first on Pharma Mirror Magazine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Checkpoint inhibitors, Enhertu in spotlight as ASCO resumes in-person meetings

pharmaphorum

At six months, all patients had no evidence of a tumour, allowing them to skip the chemotherapy and/or surgery that would normally be their next treatment. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

Chemotherapy still accounted for 72.6% Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% While all of the top ten best-selling oncology drugs in the US in 2019 were innovative therapies, four out of the top ten best-selling oncology drugs in China were for conventional chemotherapy. “In

article thumbnail

Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab

pharmaphorum

There’s potential for combination drugs, paving the way for less toxic chemotherapy-free cancer drugs. Richard also contributes to pharmaphorum’s digital magazine, DeepDive. Genmab’s HexElect antibodies are based on co-dependent antibodies with dual targeting plus enhanced potency and selectivity.